Matches in Wikidata for { <http://www.wikidata.org/entity/Q65474040> ?p ?o ?g. }
Showing items 1 to 58 of
58
with 100 items per page.
- Q65474040 description "assaig clínic" @default.
- Q65474040 description "clinical trial" @default.
- Q65474040 description "clinical trial" @default.
- Q65474040 description "clinical trial" @default.
- Q65474040 description "clinical trial" @default.
- Q65474040 description "ensaio clínico" @default.
- Q65474040 description "ensayo clínico" @default.
- Q65474040 description "ensayu clínicu" @default.
- Q65474040 description "essai clinique" @default.
- Q65474040 description "klinisch onderzoek" @default.
- Q65474040 description "клінічне випробування" @default.
- Q65474040 name "DORADO-AC-EX - A Long-Term Safety Extension Study to the Phase 3 DORADOC-AC Study (Protocol DAR-312) of Darusentan in Resistant Hypertension" @default.
- Q65474040 name "DORADO-AC-EX - A Long-Term Safety Extension Study to the Phase 3 DORADOC-AC Study" @default.
- Q65474040 type Item @default.
- Q65474040 label "DORADO-AC-EX - A Long-Term Safety Extension Study to the Phase 3 DORADOC-AC Study (Protocol DAR-312) of Darusentan in Resistant Hypertension" @default.
- Q65474040 label "DORADO-AC-EX - A Long-Term Safety Extension Study to the Phase 3 DORADOC-AC Study" @default.
- Q65474040 prefLabel "DORADO-AC-EX - A Long-Term Safety Extension Study to the Phase 3 DORADOC-AC Study (Protocol DAR-312) of Darusentan in Resistant Hypertension" @default.
- Q65474040 prefLabel "DORADO-AC-EX - A Long-Term Safety Extension Study to the Phase 3 DORADOC-AC Study" @default.
- Q65474040 P1050 Q65474040-941EB8C2-9486-4707-8946-ED01260D8DCB @default.
- Q65474040 P1132 Q65474040-8EF9EFCA-C0B4-4F41-8252-EE3A5E26E713 @default.
- Q65474040 P1476 Q65474040-0813249B-7909-4D32-AC2B-4650E0F10CA4 @default.
- Q65474040 P17 Q65474040-421F8DD1-C750-41CA-89B3-78E0DC8B7756 @default.
- Q65474040 P17 Q65474040-4B57762B-1F28-4D9C-979D-C1787F20BA33 @default.
- Q65474040 P17 Q65474040-5116DD23-3D58-4D86-B5CB-E84981BE6445 @default.
- Q65474040 P17 Q65474040-94EB6798-A14F-401B-9F36-5E632A031EDA @default.
- Q65474040 P1813 Q65474040-A914193F-4D68-48F8-93F3-3C59D7AEC9A4 @default.
- Q65474040 P2899 Q65474040-8880217A-3D23-4F7F-A57F-9E4F70C4E5F6 @default.
- Q65474040 P3098 Q65474040-B74E3A84-FB36-4923-86C7-939CFED949B4 @default.
- Q65474040 P31 Q65474040-655986AF-6CCE-427E-9AAE-1425AD1E98F5 @default.
- Q65474040 P4135 Q65474040-B90D4597-B2F1-47DA-925B-39E45847AD00 @default.
- Q65474040 P580 Q65474040-D6A429F0-C6BB-4C67-BD8B-3770BFE4079F @default.
- Q65474040 P582 Q65474040-B2424E66-FC30-46F2-BC87-88E72781C8C7 @default.
- Q65474040 P6099 Q65474040-63F7B1EE-BF4D-49AC-8847-F02AAE45AE4A @default.
- Q65474040 P6153 Q65474040-5104BF00-FB5B-4452-9725-4640908E8809 @default.
- Q65474040 P6153 Q65474040-729091A3-4E3B-4238-876B-68BAF30AAA75 @default.
- Q65474040 P6153 Q65474040-D1CE3DFB-5EA8-4671-BB03-38CD5FBA3E9E @default.
- Q65474040 P6153 Q65474040-DAF9C5E4-3DCD-4392-B4D7-DE495300E8F6 @default.
- Q65474040 P8363 Q65474040-450F9C60-F987-4008-A179-06F31BD484F3 @default.
- Q65474040 P1050 Q41861 @default.
- Q65474040 P1132 "+661" @default.
- Q65474040 P1476 "A Double-Blind, Active-Controlled, Long-Term Safety Extension Study of Optimized Doses of Darusentan in Subjects With Resistant Hypertension Despite Receiving Combination Therapy With Three or More Antihypertensive Drugs, Including a Diuretic, as Compared to Guanfacine (Protocol DAR-312-E)" @default.
- Q65474040 P17 Q155 @default.
- Q65474040 P17 Q30 @default.
- Q65474040 P17 Q408 @default.
- Q65474040 P17 Q414 @default.
- Q65474040 P1813 "Darusentan" @default.
- Q65474040 P2899 "+35" @default.
- Q65474040 P3098 "NCT00389675" @default.
- Q65474040 P31 Q30612 @default.
- Q65474040 P4135 "+80" @default.
- Q65474040 P580 "2007-05-01T00:00:00Z" @default.
- Q65474040 P582 "2010-02-01T00:00:00Z" @default.
- Q65474040 P6099 Q42824827 @default.
- Q65474040 P6153 Q1517021 @default.
- Q65474040 P6153 Q30269721 @default.
- Q65474040 P6153 Q30270062 @default.
- Q65474040 P6153 Q49212 @default.
- Q65474040 P8363 Q78089383 @default.